Bisphenol A is a widely used industrial chemical with many potential sources of human exposure. Bisphenol A is a weak estrogen and has been implicated as an "endocrine disruptor". This term is used for a variety of chemicals encountered in the environment which have estrogenic activity. It has been postulated that human exposure to these chemicals may elicit unwanted estrogenic effects in humans such as reduced fertility, altered development and cancer. Up to now the body burden of bisphenol A in humans is unknown. Therefore, we investigated the metabolism and toxicokinetics of bisphenol A in humans exposed to low doses since systemic bioavailability has a major influence on possible estrogenic effects in vivo. Human subjects (three males and three females, and four males for detailed description of blood kinetics) were administered d(16)-bisphenol A (5 mg). Blood and urine samples were taken in intervals (up to 96 h), metabolites formed were identified by GC/MS and LC-MS/MS and quantified by GC/MS-NCI and LC-MS/MS. d(16)-Bisphenol A glucuronide was the only metabolite of d(16)-bisphenol A detected in urine and blood samples, and concentrations of free d(16)-bisphenol A were below the limit of detection both in urine (6 nM) and blood samples (10 nM). d(16)-Bisphenol A glucuronide was cleared from human blood and excreted with urine with terminal half-lives of less than 6 h; the applied doses were completely recovered in urine as d(16)-bisphenol A glucuronide. Maximum blood levels of d(16)-bisphenol A glucuronide (approximately 800 nM) were measured 80 min after oral administration of d(16)-bisphenol A (5 mg). The obtained data indicate major species differences in the disposition of bisphenol A. Enterohepatic circulation of bisphenol A glucuronide in rats results in a slow rate of excretion, whereas bisphenol A is rapidly conjugated and excreted by humans due to the absence of enterohepatic circulation. The efficient glucuronidation of bisphenol A and the rapid excretion of the formed glucuronide result in a low body burden of the estrogenic bisphenol A in humans following oral absorption of low doses.

The compound 2,2',6,6'-Tetrabromo-4,4'-isopropylidenediphenol (tetrabromobisphenol A, TBBPA) is used as a reactive and additive flame retardant. This review evaluates the mammalian toxicology of TBBPA and summarizes recent human exposure and risk assessments. TBBPA has a low potential for systemic or reproductive toxicity, and no-observed-adverse-effect-levels were greater than 1,000 mg/kg body weight (bw)/day in a 90-day oral toxicity study, a developmental toxicity study and a two-generation reproductive and developmental toxicity study. Some interactions of TBBPA with hormone-mediated pathways were noted in vitro; however, when studied in vivo, TBBPA did not produce adverse effects that might be considered to be related to disturbances in the endocrine system. Therefore, in accordance with internationally accepted definitions, TBBPA should not be considered an "endocrine disruptor." Furthermore, TBBPA is rapidly excreted in mammals and therefore does not have a potential for bioaccumulation. Measured concentrations of TBBPA in house dust, human diet and human serum samples are very low. Daily intakes of TBBPA in humans were estimated to not exceed a few ng/kg bw/day. Due to the low exposures and the low potential for toxicity, margins of exposures for TBBPA in the human population were between 6 × 10(4) (infants) to 6 × 10(7) (adults). Exposures of the general population are also well below the derived-no-effect-levels derived for endpoints of potential concern in REACH.

No abstract

No abstract

Daidzein is an estrogenic isoflavone present in many plants and therefore consumed in relatively high doses by humans. Daidzein has a low affinity for the estrogen receptor (3 orders of magnitude lower than estradiol) and has been demonstrated to have estrogenic effects in rodents after administration of high doses. We have studied the disposition and biotransformation of daidzein in rats fed a diet low in isoflavone content. Four male and four female Fischer 344 rats were orally administered 100 mg/kg daidzein; excreted urine and feces were collected for 96 h and unchanged daidzein as well as formed metabolites were quantified by HPLC. In urine of male rats, daidzein, daidzein-glucuronide, and daidzein-sulfate were excreted; in females, only unchanged daidzein and daidzein-glucuronide were present. Total urinary excretion of daidzein accounted for < 10% of dose in both males and females. The major pathway of daidzein elimination was excretion of unchanged daidzein with feces. Reductive daidzein-metabolites likely formed by intestinal microflora (equol, O-desmethylangolensin) were excreted with feces in small amounts (< 5% of dose). Excretion of daidzein and metabolites with urine and feces was rapid with elimination half-lives of less than 12 h; daidzein concentrations in urine and feces were below the limit of detection 36 h after daidzein administration. The results suggest that daidzein is only poorly absorbed from the gastrointestinal tract in rodents. Absorbed daidzein is rapidly eliminated both unchanged and as conjugates with urine. The inefficient absorption of daidzein from the gastrointestinal tract and the rapid excretion may explain the weak estrogenicity of daidzein seen in vivo in rodents when compared to other estrogenic chemicals with comparatively low affinity to the estrogen receptor.